On November 29, 2018 Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, reported the company will present two posters at the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4 – 8, 2018 in San Antonio, Texas (Press release, BioThera Solutions, NOV 29, 2018, View Source [SID1234531722]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster, entitled "BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer," will present preclinical data that highlight advantages of BAT8001 as a potential treatment for breast cancer patients. An abstract of the presentation is currently available on SABCS website.
Presentation details are as follows:
Poster Session: Treatment: Her2-targeted therapy
Session Date and Time: Saturday, December 8, 7:00 am – 9:00 am
Location: Poster Area/Exhibition Hall
Poster Board Number: P6-17-39
The second poster, entitled "BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of Trop-2 positive Triple Negative Breast Cancer," will present preclinical data that highlight advantages of BAT8003 as a potential treatment for triple negative breast cancer patients. An abstract of the presentation is currently available on SABCS website.
Presentation details are as follows:
Poster Session: Treatment: Novel Targets and Targeted Agents
Session Date and Time: Saturday, December 8, 7:00 am – 9:00 am
Location: Poster Area/Exhibition Hall
Poster Board Number: P6-20-16
About BAT8001
BAT8001 is an investigational HER2-ADC being evaluated in multiple tumor types. HER2 is a naturally occurring receptor that is overexpressed in many types of cancer, including breast cancer and gastric cancer. BAT8001 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. BAT8001 is currently being evaluated in a Phase 3 clinical trial for the treatment of metastatic breast cancer patients (more information on the trial is available at View Source (CTR20180157)). The BAT8001 clinical study program will expand beyond metastatic breast cancer to other HER2-positive cancers, including gastric cancer, over the next 12 months.
About BAT8003
BAT8003 is an investigational Trop-2-ADC being evaluated in multiple tumor types. Trop-2 is a naturally occurring receptor that is overexpressed in many types of cancer, including triple negative breast cancer and gastric cancer. BAT8003 is being developed for use as a single agent and in combination with other agents for the treatment of multiple cancers. A Phase 1 clinical trial evaluating the pharmacodynamics and safety of BAT8003 is scheduled to begin in 2019Q1.
About Antibody-Drug Conjugates
Antibody-drug Conjugates or ADCs are designed to harness the targeting ability of monoclonal antibodies (mAbs) to deliver cytotoxic agents selectively to tumor cells by linking the monoclonal antibody and cytotoxic agent through a chemical linker. An ideal ADC consists of: 1) a highly selective mAb for a tumor-associated antigen that has little or no expression on normal cells, 2) a potent cytotoxic agent designed to induce target cell death after being internalized in the tumor cell and released and 3) a chemical linker that is stable in circulation but releases the cytotoxic agent in target cells. By selectively delivering a cytotoxic agent directly inside a tumor cell, ADCs increase the safety and tolerability of the cytotoxic agent relative to giving the cytotoxic agent systemically to the patient.